CymaBay Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1991-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.cymabay.com
Clinical Trials
59
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-09-29
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06060665
- Locations
- 🇺🇸
The Institute for Liver Health II LLC dba Arizona Clinical Trials; Arizona Liver Health, Chandler, Arizona, United States
🇺🇸California Liver Research Institute, Pasadena, California, United States
🇺🇸University of California (UC) Davis Medical Center, Sacramento, California, United States
RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2020-11-09
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT04620733
- Locations
- 🇺🇸
The Institute for Liver Health DBA Arizona Liver Health, Chandler, Arizona, United States
🇺🇸Arkansas Diagnostic Center, Little Rock, Arkansas, United States
🇺🇸Stanford University School of Medicine, Palo Alto, California, United States
Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406
- Conditions
- Healthy Volunteers
- Interventions
- Drug: CB-0406 100 mgDrug: CB-0406 200 mgDrug: CB-0406 800 mgDrug: CB-0406 1,000 mgDrug: Matched placeboDrug: CB-0406 400 mg
- First Posted Date
- 2020-07-13
- Last Posted Date
- 2021-06-11
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04467684
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Conditions
- Primary Biliary Cholangitis
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2022-08-02
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT03602560
- Locations
- 🇺🇸
Institute for Liver Health, Chandler, Arizona, United States
🇺🇸Mayo Clinic Arizona - PPDS, Phoenix, Arizona, United States
🇺🇸The Institute for Liver Health-Tucson, Tucson, Arizona, United States
A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: Placebos
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 181
- Registration Number
- NCT03551522
- Locations
- 🇺🇸
CymaBay Research Site, Rollingwood, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- Next